Back to Journals » OncoTargets and Therapy » Volume 7

Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma

Authors Bodiford A, Bodge M, Talbott M, Reddy N

Received 13 August 2014

Accepted for publication 24 September 2014

Published 24 October 2014 Volume 2014:7 Pages 1971—1977


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Dr Faris Farassati

Andrew Bodiford,1 Megan Bodge,1 Mahsa S Talbott,1 Nishitha M Reddy2

1Department of Pharmacy, 2Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

Abstract: The peripheral T-cell lymphomas are a rare and heterogeneous group of mature T-cell lymphomas with limited available therapies. The outcome of frontline chemotherapy regimens has been disappointing, with a long-term survival of only 20%–30%. There is an urgent need to optimize induction therapy by incorporating novel agents that target the dysregulated pathways. Histone deacetylase inhibitors that induce acetylation of histones and enhance apoptosis have shown promising activity. In this article, we summarize the role of histone deacetylase inhibitors and specifically discuss pharmacokinetics, efficacy, and toxicity of the recently US Food and Drug Administration-approved agent belinostat for its use in patients with relapsed/refractory peripheral T-cell lymphoma.

Keywords: histone deacetylase inhibitor, pharmacokinetics, cutaneous T-cell lymphoma

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]